Develops blood-based diagnostic tests for early detection of cancer and other diseases.
VolitionRx Limited, headquartered in Austin, Texas, is a prominent multinational company specializing in epigenetics. Its primary focus lies in pioneering the development of innovative blood tests designed to diagnose a variety of cancers and other diseases on a global scale. The company's flagship products include Nu.Q, which serves as a robust tool for cancer detection, and Nu.Q Nets, designed to monitor immune system dynamics. Additionally, VolitionRx offers Nu.Q Vet, a cancer screening test tailored for veterinary applications, highlighting its diverse application of advanced diagnostic technologies.
Central to VolitionRx's groundbreaking capabilities is its proprietary Nucleosomics technology platform, which forms the foundation for its suite of blood tests. This platform includes Nu.Q Capture, facilitating the capture and concentration of biological samples to enhance diagnostic accuracy, and Nu.Q Discover, a solution dedicated to profiling nucleosomes for deeper insights into diseasse biomarkers. Through continuous innovation and strategic advancements in epigenetic diagnostics, VolitionRx remains at the forefront of transforming healthcare by providing reliable and accessible diagnostic solutions worldwide.
With a commitment to leveraging cutting-edge science and technology, VolitionRx Limited continues to expand its portfolio and explore new avenues for diagnostic development. By integrating rigorous research with clinical expertise, the company aims to empower healthcare professionals and improve patient outcomes through early and precise disease detection.